Explorer les evidences

26 %Among 393 HCV antibody-positive partner participants, 104 (26%) knew their HCV antibody status.

Kenyahépatite Cpublié 2024The Lancet. Global healthPubMeddocument de 7 observations

2 %The pooled HCV prevalence for the low-risk group in Kenya was 2.0%.

Kenyahépatite Cpublié 2024Journal of epidemiology and global healthPubMeddocument de 8 observations

12,4 %Among 2386 partners of HIV-positive persons who inject drugs in Kenya, 297 (12.4%) tested HCV antibody positive.

Kenyahépatite Cpublié 2022BMC infectious diseasesPubMeddocument de 4 observations

2 244 peopleTreating 2244 people who inject drugs over 2021–2025 could reduce hepatitis C virus incidence by 90% by 2030 in Kenya.

Kenyahépatite Cobservé 2021-2025publié 2022AIDS (London, England)PubMeddocument de 8 observations

1,21 %Hepatitis C virus (HCV) accounted for 1.21% of discarded blood units due to transfusion transmissible infections at the Kwale Satellite Blood Transfusion Centre in Kenya from 2018 to 2022.

Kenyahépatite Cobservé 2018-2022publié 2024BMC public healthPubMeddocument de 7 observations

55,8 %HCV genotypes were distributed as follows: 53 (55.8%) genotype 1a, 39 (41.1%) genotype 4a, and 3 (3.2%) genotype 1a/4a.

Kenyahépatite Cpublié 2022Journal of viral hepatitisPubMeddocument de 8 observations

0 casesNo instances of HIV, syphilis, or hepatitis C were identified in the tested blood samples.

Kenyahépatite C · syphilis · VIH/sidapublié 2026Global health, epidemiology and genomicsPubMeddocument de 3 observations

34,5 %A third of the included studies on HCV in Kenya were from Nairobi, accounting for 34.5%.

Kenyahépatite Cpublié 2024Journal of epidemiology and global healthPubMeddocument de 8 observations

38 %Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%).

Kenyahépatite B · hépatite Cpublié 2008PloS oneeurope_pmcdocument de 4 observations

19,4 %Among 3152 participants who inject drugs in Kenya, 610 (19.4%) were HCV antibody-positive.

Kenyahépatite Cpublié 2025The International journal on drug policyPubMeddocument de 6 observations

85 countAmong 92 PWID who initiated HCV treatment, 85 (92%) completed treatment.

Kenyahépatite Cpublié 2023The International journal on drug policyPubMeddocument de 7 observations

26,5 %Among people who inject drugs in Kenya, women were HCV antibody-positive at a rate of 26.5%, compared to 18.6% among men.

Kenyahépatite Cpublié 2026The International journal on drug policyPubMeddocument de 5 observations

20,7 %20.7% of the studies on HCV in Kenya included injection drug users.

Kenyahépatite Cpublié 2024Journal of epidemiology and global healthPubMeddocument de 8 observations

31 %Half of the studies on HCV in Kenya included HIV-infected individuals (31%) or injection drug users (20.7%).

Kenyahépatite C · VIH/sidapublié 2024Journal of epidemiology and global healthPubMeddocument de 8 observations

79 countAmong 92 PWID who initiated HCV treatment, 79 (86%) achieved sustained virologic response (SVR).

Kenyahépatite Cpublié 2023The International journal on drug policyPubMeddocument de 7 observations

85,9 %Among 92 participants who initiated treatment, 79 (85.9%) achieved SVR.

Kenyahépatite Cpublié 2022Journal of viral hepatitisPubMeddocument de 8 observations

41 %Among PWID who initiated HCV treatment, 41% were genotype 4a.

Kenyahépatite Cpublié 2023The International journal on drug policyPubMeddocument de 7 observations

54 %Among 393 HCV antibody-positive partner participants, 213 (54%) had viraemia.

Kenyahépatite Cpublié 2024The Lancet. Global healthPubMeddocument de 7 observations

19,3 %Among 3152 people who inject drugs enrolled in Kenya, 19.3% were HCV antibody-positive.

Kenyahépatite Cpublié 2026The International journal on drug policyPubMeddocument de 5 observations

12 %Among 4597 enrolled partner participants, 393 (12%) were HCV antibody positive.

Kenyahépatite Cpublié 2024The Lancet. Global healthPubMeddocument de 7 observations

55 %Among PWID who initiated HCV treatment, 55% were genotype 1a.

Kenyahépatite Cpublié 2023The International journal on drug policyPubMeddocument de 7 observations

50 %In 2020, opioid agonist therapy and needle and syringe programmes averted between 50.0% and 66.1% of hepatitis C virus infections among people who inject drugs in Kenya.

Kenyahépatite Cobservé 2020publié 2022AIDS (London, England)PubMeddocument de 8 observations

975 USD_per_DALY_averterThe cost per disability-adjusted life-year averted for the HCV screening and treatment intervention among people who inject drugs in Nairobi was $975.

Kenyahépatite Cpublié 2022Addiction (Abingdon, England)PubMeddocument de 4 observations

11 %People who inject drugs in Kenya have hepatitis C virus prevalence ranging from 11% to 36% across settings.

Kenyahépatite Cpublié 2022AIDS (London, England)PubMeddocument de 8 observations

92,4 %Among 92 participants who initiated treatment, 85 (92.4%) completed treatment.

Kenyahépatite Cpublié 2022Journal of viral hepatitisPubMeddocument de 8 observations